SHANGHAI, Aug. 25, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, and Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm," Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical company headquartered in Hong Kong with 20 years of operations in China, today announced that the two companies have signed an agreement whereby WuXi's Laboratory Testing Division (LTD) will be the exclusive supplier of laboratory testing services for Lee's Pharm. These services will include LTD's entire portfolio of discovery and IND/NDA package services, including chemistry analytical services, in vitro and in vivo biology, oncology, immunology, in vitro ADME, pharmacokinetic / pharmacodynamic studies, toxicology, and clinical bioanalysis. LTD will provide dedicated program management, streamline project coordination across WuXi, and allocate the necessary resources and R&D development efforts for Lee's Pharm programs.
"We are delighted to become exclusive supplier of the broad range of laboratory testing services for the drug discovery portfolio of Lee's Pharm," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "WuXi has been building a comprehensive and integrated R&D enabling platform, and this strategic collaboration is an example of delivering that platform to serve our innovative partners."
"WuXi's impressive platform of lab testing services will allow our compounds to advance seamlessly through discovery, preclinical, and clinical development," commented Dr. Benjamin Li, Executive Director and CEO of Lee's Pharm. "We are confident that this strategic partnership with LTD will streamline and accelerate our drug discovery program."
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi's Laboratory Testing Division (LTD) provides a comprehensive and integrated testing platform throughout the drug discovery and development process. With operations in both China and the U.S., it provides services and solutions in chemical analysis, in vivo and in vitro biology, oncology, immunology, drug metabolism and pharmacokinetic / pharmacodynamic studies, toxicology, bioanalysis, and medical device testing. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.
About Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited (Lee's Pharm) is a research-based biopharmaceutical company headquartered in Hong Kong, with more than 20 years of operation in China's pharmaceutical industry. It is fully integrated, with a strong organization in drug development, manufacturing, sales and marketing. It has established extensive partnerships with more than 20 international companies and currently has 14 marketed products. Lee's Pharm focuses on several key disease areas such as cardiovascular diseases, oncology, gynecology, dermatology and ophthalmology. The company's research and development program has produced 30 product candidates resulting from internal R&D efforts and collaborations with U.S., European and Japanese companies, including promising compounds to treat liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.